Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07221500 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 37 → 40 locations Eligibility criteria expanded, about 17 words · Secondary endpoints: details revised at 3 of 13 entries · Study description expanded, about 3 words Show 3 more changesShow less
    • Eligibility criteria expanded, about 17 words
    • Secondary endpoints: details revised at 3 of 13 entries
    • Study description expanded, about 3 words
  2. Study sites revised (37)v13 See this version in full on ClinicalTrials.gov ↗
  3. Study sites: 35 to 37v12
  4. Trial sites expanded: 32 → 35 locationsv11
  5. Study sites: 30 to 32v10
  6. Trial sites expanded: 24 → 30 locationsv9
  7. Trial sites expanded: 20 → 24 locations Eligibility criteria expanded, about 35 wordsv8 Show 1 more changeShow less
    • Eligibility criteria expanded, about 35 words

    See this version in full on ClinicalTrials.gov ↗

  8. Study sites: 18 to 20v7
  9. Study sites: 14 to 18v6
  10. Study sites: 10 to 14v5
  11. Primary endpoint revised Study sites: 6 to 10 · Eligibility criteria expanded, about 16 words · Secondary endpoints: 10 to 13v4 Show 3 more changesShow less
    • Study sites: 6 to 10
    • Eligibility criteria expanded, about 16 words
    • Secondary endpoints: 10 to 13

    See this version in full on ClinicalTrials.gov ↗

  12. Study sites: 5 to 6v3
  13. Study sites: 2 to 5v2
  14. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibitor. The main purpose of this study is to test if NX-5948 (bexobrutideg) works to treat patients with CLL/SLL. Participation could last up to 5 years, and possibly longer, if the disease does not progress.
Trial Details
NCT Number NCT07221500
Lead Sponsor Nurix Therapeutics, Inc.
Conditions Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov